EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times.
The biotech has been singled out for a $1.6bn payment for US Covid-19 vaccine development.
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.